All Times EDT
Keywords: VAF, ctDNA, driver mutation, Overall Survival time, real world evidence data
Clinical implementation of mutational analysis for NGS-based assays has largely been of a binary nature with pathogenic mutations being reported as either positive or negative. Actionability on the continuous output of variant allele frequency (VAF) has not been well characterized in the clinical setting, limiting its use. In this talk, the association of allele frequency of clinically relevant short variants in circulating free DNA (cfDNA) with overall survival (OS) for patients using real-world data was also assessed. The results of the association analysis indicated that VAF of the predictive biomarker mutation negatively correlated with OS of NSCLC patients who were under different treatment option. The results from this study may support ctDNA a potential surrogate endpoint of the clinical outcome.